MicroRNAs are a class of noncoding small RNAs that regulate the expression of nearly 30% of all the human genes and participate in all fundamental cell processes. Genome-wide analysis has revealed that human placenta expresses more than 600 miRNA species, including placenta-specific ones with high levels of expression. Comparative analysis also has revealed many differentially expressed miRNAs with either high or low levels of expression in human placentas from normal versus preeclamptic pregnancies, indicating an important role of miRNAs in normal and pathological placental physiology. Although limited information is currently available as to how miRNA regulates human placental development and function, there are studies suggesting that preeclampsia-associated differentially expressed miRNAs possess critical roles in regulating placental development and function via targeting specific genes with diverse known functions. Herein we summarize the current findings regarding the expression of placental miRNAs and their function, especially in the trophoblast cells. We have recently found that the angiogenesis-associated miR-17-family miRNAs are upregulated in preeclamptic compared with normotensive placentas and they target the ephrin-B2/Eph receptor B4 (EPHB4) system. Because ephrin-B2 and EPHB4 has been previously shown to play a crucial role in trophoblast invasion into maternal spiral artery and vascular patterning during early human placental development, the miR-17-ephrin-B2/EPHB4 pathway seems to be a novel miRNA pathway for regulating normal and aberrant placental development during preeclampsia.
INTRODUCTION
Preeclampsia (PE) is a human pregnancy-specific disorder characterized by new onset of hypertension and proteinuria; it affects 5%-8% of all pregnancies worldwide and remains as a leading cause of maternal and neonatal mortality and morbidity [1, 2] . Although the etiology and pathogenesis of PE remain elusive, the placenta is definitely involved in the pathogenesis of PE because removal of the placenta eradicates the clinical manifestations of PE [3] . Both conventional and microarray approaches have identified a substantial number of differentially expressed (DE) genes in the transcriptome of human placentas from PE compared with normotensive healthy term deliveries [4] [5] [6] , clearly suggesting differential gene expression is associated with the pathogenesis of PE. Genetic and epigenetic pathways have been suspected to cause the alterations of placental transcriptome by PE [7, 8] . However, how placental gene expression is differentially regulated in PE pregnancy is largely unknown.
The miRNAs represent a class of 21-25-nucleotide noncoding small RNAs that negatively regulate gene expression primarily at the level of posttranscription. Since the discovery of the first miRNA, lin-4, in Caenorhabditis elegans in 1993 [9, 10] , a large number of miRNAs have been identified in many species. In human, more than 1000 miRNAs have been detected to date, and this number is still increasing [11, 12] . In mammals, miRNAs are highly conserved across species [13] . It is estimated that miRNAs regulate the expression of ;30% of all human genes [14] , thereby participating in nearly all fundamental cellular processes, including cell differentiation, proliferation, migration and apoptosis, etc. [15] . In recent years, miRNAs have emerged as one of the hottest research topics in biology and diseaserelated pathologies including PE. Genome-wide analysis of the miRNA species (miRNAome) expressed in human placenta has identified a dozen PE-associated DE miRNAs. A few functional studies have also suggested that miRNAs serve as an important pathway for regulating placental development and function. In this review, with a brief introduction of human placental development and the biosynthesis and function of miRNAs, we summarize the latest findings on the expression and function of miRNAs in the placenta. According to our findings we propose a novel miRNA pathway for the regulation of placental development as related to the pathogenesis of PE.
PLACENTAL DEVELOPMENT AND THE PATHOGENESIS OF PE
Mammalian development is characterized by the early specification of the trophoblast lineage whose dedicated function lies in the survival of embryo and fetal development in utero. In eutherians, the polarized outer layer of epithelial cells termed trophectoderm surrounding the inner cell mass of the implanting embryo develops as cytotrophoblasts (CTBs) that function as placental stem cells during early placental development [16] . The CTBs further differentiate into specialized villous cell types via the villous and extravillous pathways [17, 18] . The villous pathway directs the proliferative mononucleated CTBs' fusion to form an external layer of terminally differentiated nonproliferative multinucleated syncytiotrophoblasts (STBs). STBs are endocrine cells synthesizing hormones for pregnancy, including human chorionic gonadotropin, placental lactogen, and steroid hormones; they cover all placental chorionic villi and come into direct contact with maternal blood, and thus are crucial for maternal-fetal exchanges; they are human leukocyte antigen-G (HLA-G)-positive cells and protect the allograft fetus from immune rejection [19] . In human, around Day 14 after implantation, CTBs break through the STB layer, differentiating via the extravillous pathway to form columns of the extravillous trophoblasts (EVTs) to invade the uterine stroma. The motile invasive tip cells of the EVT columns move laterally to form the trophoblastic shell and longitudinally to invade deeply the decidua and the deeper portion of the myometrium, where these cells profoundly remodel the uterine spiral arteries [20] [21] [22] . The endothelial and smooth muscle cells of the spiral arteries are replaced by EVTs, transforming the spiral arteries from high-resistance and low-flow vessels into dilated vessels with more than 10-fold-increased blood flow due to a muchreduced pressure [23] . This is a process of vascular mimicry, which is called endovascular transformation or pseudovasculogenesis [24] because the invading trophoblasts convert from an epithelial to an endothelial phenotype [25] . Trophoblastinduced spiral artery remodeling is crucial for a healthy pregnancy because shallow EVT invasion and incomplete endovascular transformation impairs spiral artery remodeling, resulting in reduced blood flow in the maternal-fetal and placental interface in the first trimester of gestation. This has been recognized as the leading pathology of various pregnancy disorders, including PE, gestational diabetes, intrauterine growth restriction, and low birth weight [4, 5, 26] .
In the case of PE, eradication of the clinical manifestations after removal of the placenta [3] clearly indicates that aberrant placental development is involved in the pathogenesis of PE. Although its etiology and pathogenesis remain elusive, the current literature for the pathogenesis of PE favors a two-stage model hypothesis that applies to a majority of all PE cases [1, 27] . The first stage is poor placentation as evidenced by color Doppler ultrasound demonstration of a tight link between reduced spiral arterial blood flow before the 20th week of gestation and a greatly increased risk of developing PE [28, 29] . Contrasting to a spectrum of physiological changes that normally occur in the maternal spiral arteries, e.g., loss of endothelial lining and musculoelastic tissue, interstitial CTB invasion is often shallow and endovascular invasion does not proceed beyond the terminal portions of the vessels in PE. The mean external diameter of the myometrial vessels is less than half that of similar vessels from normal pregnancies [30] [31] [32] [33] . In addition, fewer vessels show evidence of trophoblast invasion [34] . As a result, impaired spiral artery remodeling precludes an adequate response to gestation-related fetal demands of increased blood flow. This causes placental ischemia/hypoxia, resulting in trophoblast debris [35] , and induces placental secretion of harmful factors, such as soluble fms-like tyrosine kinase 1 (sFlt1) [36, 37] , inflammatory cytokines [38, 39] , and antibodies of angiotensin-I receptors [40] , to be circulated into the maternal blood. Overall, these changes lead to the second stage of the maternal manifestations.
The second stage of the disease is the maternal response to abnormal placentation, which is featured by systemic endothelial dysfunction [41] . Of note, endothelial dysfunction occurs not only in the maternal but also in the placental vasculature [42] [43] [44] [45] . Many circulating factors, such as sFlt1, soluble endoglin, tumor necrosis factor-a, interleukin 1, fibronectin, and factor VIII antigen [36-39, 46, 47] , etc., have been found to be elevated in the blood of pregnant women with PE [38, 39] . Concomitantly, the levels of endothelium-derived vasodilators such as nitric oxide (NO) [48] [49] [50] and prostacyclin [51] are decreased, and the level of S-nitrosoproteins (NO reservoir) is increased in maternal serum [52] and placenta [53] in PE. An imbalance between circulating harmful and beneficial factors further leads to systemic inflammatory responses and endothelial dysfunction in many organ systems, including the vasculature, kidney, liver, brain, etc. Eventually, the clinical manifestations of PE occur after the 20th week of gestation with a triad symptom of rapid onset of hypertension, proteinuria, and edema secondary to increased vascular permeability in the glomeruli and peripheral tissues [1, 2] .
BIOGENESIS AND FUNCTION OF miRNAs
The miRNA biosynthesis begins with RNA polymerase IIdependent transcription of long primary transcripts (primiRNAs) from the genes encoding miRNAs, many of which reside in the introns of their host genes; these pri-miRNAs fold into distinctive stem-loop precursors [54, 55] . In mammals, the long pri-miRNAs are first processed in the nucleus by a ''microprocessor complex'' that is composed of the RNase III endonuclease Drosha and a double-stranded RNA (dsRNA)-binding protein, DGCR8, forming 60-70 nucleotide precursor miRNAs (pre-miRNAs) with stem-loop structure and 3 0 overhangs. The pre-miRNAs are then exported from the nucleus into the cytoplasm by Exportin 5 (Exp 5) and further processed by another RNase III enzyme, Dicer, into miRNA duplexes [56, 57] . Finally, the miRNA duplex is unwound; one strand functions as the mature miRNA, which is incorporated into the RNA-induced silencing complex (RISC) that contains Argonaute (Ago) proteins at its core [58, 59] and other proteins including DEAD-box helicase protein DP103 [60] , gemin4, and Moloney leukemia virus 10 (MOV10) [61] . The miRNA-RISC complex binds specific sites in the 3 0 -untranslated region (3 0 UTR) of target mRNAs, disabling them through deadenylation and destabilization, as well as translational repression [62, 63] (Fig. 1) .
Translational inhibition has been recognized as the main mechanism by which miRNA suppresses protein expression. The literature strongly suggests that this is largely achieved by destabilizing target mRNAs [64] based on the complementary pairing between the miRNA seed sequence centered on nucleotides 2-7 of the miRNA and the 3 0 UTR of the target mRNA [65] . As the pairing can be either a perfect or an imperfect complement, one miRNA is able to regulate the expression of multiple genes and one gene can be regulated by more than one miRNA. Although the majority of literature points to an inhibitory role of miRNA in regulating gene expression, there are studies also suggesting alternative mechanisms for miRNA to regulate gene expression. For example, miR-373 has been found to induce the expression of E-cadherin and cold-shock domain-containing protein C2 through targeting their complementary promoter sequences [66] .
PLACENTA-SPECIFIC miRNAs
Since 2007, several studies have used miRNA microarray and real-time PCR approaches to profile the genome-wide expression of miRNAs in normal and pathological human placentas. These expression studies have revealed that many specific miRNAs are expressed in human placenta [67] [68] [69] [70] . For example, our recent genome-wide screening study using miRNA array has identified that the miRNAome in normal healthy term human placenta contains more than 600 miRNAs CHEN AND WANG [71] . Other investigators have also identified more than 300 mature miRNAs in human placenta by using different arrays [72, 73] .
The miRNAome in the human placenta contains numerous miRNAs with different expression levels. Through sequencing a small RNA library constructed from human placental villous tissue, it has been found that many placental miRNAs with high levels of expression are encoded by the C19MC-cluster miRNA genes located in chromosome 19 [70] . The C19MC cluster is the largest human miRNA gene cluster discovered to date. This cluster is primate specific and is expressed almost exclusively in the placenta [67] [68] [69] [70] . The C19MC cluster spans about 100 kb at human chromosome 19q13.41, consisting of 54 predicted miRNAs; 43 have been cloned and sequenced [11, 74] . C19MC miRNAs are encoded and processed from introns of the non-protein-coding Pol-II transcripts [75] . Their expression pattern is associated with methylation status of a distal CpG-rich region located at 17.6 kb upstream of the miRNA cluster. DNA methylation profiling has identified that C19MC is regulated by genomic imprinting with only paternally inherited allele being expressed in the placenta, implicating its important role in human embryonic development similar to that of other imprinted genes such as insulinlike growth factor 2 [76] [77] [78] . Studies on the expression profile of the C19MC miRNAs in the primary human trophoblasts (PHTs) from term placenta demonstrate that they comprise the majority of human trophoblast miRNAs because they are expressed at a much higher level than the total level of all the other miRNAs expressed in the PHT. The highest-expressing C19MC miRNAs in the PHT include miR-517a, miR-517b, miR-516b, miR-525-5p, miR-512-3p, and miR-515-3p [79] . It is found that miR-517a-3p, miR-519a-3p, and miR-520c-3p are also abundantly expressed in placenta-derived mesenchymal stromal cells [80] , indicating that their placenta-specific functions are not just restricted to the trophoblast. In addition, some of these placenta-specific miRNAs have been detected in the maternal circulation throughout gestation with significant decrease after pregnancy termination, including miR-515-3p, miR-516-5p, miR-517a, miR-517c, miR-518b, miR-520a*, miR-520h, miR-525, miR-526a, and miR-526b [81, 82] . These results suggest that maternal circulating miRNAs may have the potential to be novel diagnosis agents for pregnancy disorders. Although the biological functions of the C19MC cluster in the placenta are currently unknown, it is anticipated that they are important for the maintenance of normal placental physiology because of their high levels of expression.
Apart from the abundantly expressed C19MC cluster, numerous miRNAs with relatively low levels of expression are also expressed in the human placenta. Detailed information about human placental miRNAs can be found in the published work [67] [68] [69] [70] [71] [72] [73] . Although the biological functions of only a few miRNAs have been determined in placenta using established trophoblast cell models in vitro (see below), bioinformatics analysis of the diverse genes predicted to be the targets of The miRNA biosynthesis begins with RNA polymerase II-dependent transcription of pri-miRNAs from miRNA genes that reside in the introns of their host genes. Pri-miRNAs fold into distinctive stem-loop precursors. In mammals, the long pri-miRNAs are first processed in the nucleus by a microprocessor complex that is composed of the RNase III endonuclease Drosha and a dsRNA-binding protein DGCR8, forming 60-70 nucleotide pre-miRNAs with stem-loop structure and 3 0 overhangs. The pre-miRNAs are then exported from the nucleus into the cytoplasm by Exp 5 and further processed by another RNase III enzyme, Dicer, into miRNA duplexes. Finally, the miRNA duplex is unwound; one strand functions as the mature miRNA, which is incorporated into the RISC that contains Ago proteins at its core and other proteins including DEAD-box helicase protein DP103, gemin4, and MOV10. The miRNA-RISC complex binds specific sites in the 3 0 UTR of target mRNAs, disabling them through deadenylation, destabilization, and translational repression.
PLACENTAL microRNAs AND PREECLAMPSIA placental miRNAs suggests that miRNAs are essential for normal and abnormal placental physiology.
DIFFERENTIAL EXPRESSION AND REGULATION OF HUMAN PLACENTAL miRNAs
Genome-wide comparative analyses of the miRNAomes in human placentas from healthy term pregnancy and those complicated with PE [71] [72] [73] [83] [84] [85] and preterm labor [73] have identified more than a dozen DE miRNAs that are subjected to regulation in human placenta.
By using real-time quantitative RT-PCR with TaqMan primer sets, Pineles et al. [84] first determined the expression of 157 mature human miRNAs in placental samples from PE, small-for-gestational age (SGA), PE þ SGA, and control group with spontaneous preterm labor and delivery (n ¼ 9/group) [84] . They found 153 miRNAs expressed in placenta, and 7 miRNAs (miR-210, miR-155, miR-181b, miR-182*, miR100b, miR-154*, and miR-183) were upregulated in the PE þ SGA group compared with the control group. Zhu et al. [85] then compared the miRNAomes in human placentas from normal deliveries (n ¼ 11) and those complicated by mild (n ¼ 8) and severe PE (n ¼ 15) by using the Exiqon miRNA microarray containing 455 human miRNAs, 344 mouse miRNAs, and 236 rat miRNAs. They found 34 PE-associated DE miRNAs, with 11 upregulated and 23 downregulated in severe-PE placentas compared with normal controls [71] [72] [73] [83] [84] [85] . Subsequently, several studies have analyzed the miRNAome in human placenta using microarrays with more miRNA probes. Enquobahrie et al. [72] used an Invitrogen microarray containing 1295 probes with 854 probes for human mature miRNAs and 379 novel small RNAs [72] . They found eight DE miRNAs, including upregulated miR-210, and seven downregulated miRNAs, including miR-328, miR-584, miR-139-5p, miR-500, miR-1247, miR-34c-5p, and miR-1, from PE compared with normotensive placentas (n ¼ 20/group). In another study, Mayor-Lynn et al. [73] used a customdeveloped microarray containing 1213 human probes targeting 820 mature miRNAs and 393 Invitrogen ''novel'' probes on 21 placental tissue samples from PE, spontaneous preterm delivery, and normal controls (n ¼ 7/group) with elective cesarean delivery [73] . They found 20 DE miRNAs among the three groups and confirmed several DE miRNAs by real-time PCR. Lower expression of miR-15b, miR-181a, miR-210, and miR-483-5p was detected in the preterm group compared with the control group. However, when compared between PE and normal controls, no difference was observed for these miRNAs, except for miR-15b, with lower expression in PE.
Surprisingly, each published work has reported a different set of DE miRNAs, with minimum overlapping among all the studies. The reason for the discrepancy is not known, but it likely originates from the different arrays and RNA samples used. The most commonly identified placental DE miRNA is miR-210, which is found to be upregulated in PE placentas compared with normotensive controls in most studies [72, [84] [85] [86] , except that one study reported that miR-210 is downregulated in preterm compared with normal placentas, but with no significant difference between PE and control groups [73] . We recently used the LC Sciences miRNA microarray containing 894 unique probes to cover all miRNAs available in the miRBase database (version 14.0) for analyzing the miRNAomes in human placenta from severe PE compared with normotensive term deliveries (n ¼ 3) and confirmed the DE miRNAs by real-time PCR. We also did not find significant changes in miR-210 in PE versus normotensive placentas. We found nine DE miRNAs between PE and normotensive placentas, including five upregulated miRNAs (miR-20b, miR-516a-5p, miR-512-3p, miR-2277, and miR-524-3p) and four downregulated miRNAs (miR-151-3p, miR-146a, miR-192, and miR-34c-5p). However, when real-time PCR with specific primers was used to confirm the DE miRNAs from 10 paired placental samples, we identified that the miR-17-family miRNAs (i.e., miR-17, miR-20a, and miR-20b) are significantly upregulated in PE compared with healthy term placentas [71] .
Hypoxia plays a significant role in normal and abnormal placental development [26] , and it is not surprising that hypoxia regulates trophoblast miRNA expression [87] . Mouillet et al. found seven DE miRNAs (miR-93, miR-205, miR-224, miR-335, miR-424, miR-451, and miR-491) in primary trophoblasts exposed to hypoxia using miRNA microarray and confirmed the DE ones by Northern blotting [87] . It has been found that miR-210 is hypoxia inducible in both endothelial cells and tumor cells [88, 89] . More recently, it has been reported that miRNA-210 expression was also elevated in cultured trophoblasts under hypoxic condition [86, 90] .
There is one paper published recently comparing the miRNA expression profiles between the first-and thirdtrimester human placentas. Among the 191 DE miRNAs, miRNAs in the miR-17-92 cluster, C14MC, the miR-371 cluster, and C19MC were significantly higher in the firsttrimester placentas, whereas miRNAs of the let-7 family, the miR-34 family, the miR-29 cluster, miR-195, and miR-181c were significantly upregulated in the third-trimester placentas [91] . The differential expression indicates the developmental changes of miRNA expression in placenta during pregnancy. Furthermore, it has been reported that the expression levels of both miR-517b and miR-519a change oppositely in association with the weight changes of placental villi during the first trimester. Both miR-517b and miR-519a are highly expressed in the trophoblast, and their expression is associated with the weight of villi in the same gestational week during the first trimester; miR-517b is upregulated in the light villi, whereas the expression of miR-519a is upregulated in the heavy villi. These data suggest their opposite role in regulation of trophoblast proliferation [92] and thus a role of miRNAs in placental development.
miRNA-DIRECTED GENE EXPRESSION IN PLACENTAL DEVELOPMENT AND FUNCTION
It is clear that miRNAs play an essential role in the regulation of placental development and function, because disabling miRNA machinery because of a mutation in mouse Ago2 causes malformation of placental labyrinthine layer with a greatly reduced thickness and death of the mutant embryos at midgestation [93] . Furthermore, global miRNA reduction in CTBs through small interfering RNA (siRNA)-mediated knockdown of Dicer significantly enhances cell proliferation in cultured first-trimester placental explants [94] , implicating a negative regulatory effect of miRNAs in trophoblast cells. Gain and loss of function studies using established trophoblast cell lines and primary trophoblast cell culture models have also suggested critical roles of some DE miRNAs in placental development and angiogenesis as well as functionality of the placenta (see below). However, the current understanding of the roles that placenta-specific miRNAs play in the regulation of placental development and function is still in its very early stage. Most, if not all, of the published work has been focused on profiling miRNA expression in placenta from normal versus disease-affected pregnancies. Although bioinformatics analysis for target prediction suggests that placenta dysfunction-CHEN AND WANG associated DE miRNAs participate in the regulation of numerous fundamental cellular processes in the placenta, the biological functions of the majority of the placenta-specific miRNAs are awaiting determination. In Table 1 , we summarize the current literature on the genes that have been identified to be regulated by placenta-specific miRNAs as related to placental development and function.
Functional studies with several widely used choriocarcinoma cell lines have suggested multiple regulatory roles of miRNAs in trophoblast cells. In human placental choriocarcinoma-derived JEG-3 cells, overexpression of miR-152 suppressed HLA-G expression and increased natural killer cellmediated cytolysis, suggesting its function in the immune system [95] . In another human placental choriocarcinoma cell line, JAR cells, overexpression of miR-34a inhibits cell invasion by targeting Notch1 and Jagged1, and possibly plasminogen activator inhibitor-1 [96, 97] . The expression of miRNA-199b has been found to be downregulated in choriocarcinomas compared with noncancer trophoblast tissues; miR-199b seems to promote proliferation and tumorigenesis of trophoblast cells via inhibiting the protein phosphatase 2A inhibitor [98] . We have recently observed that forced miR-20b expression inhibits cell fusion (syncytialization) and induces the expression of a set of endothelial cell markers in BeWo cells (Wang and Chen, unpublished data), implicating a potential role of miR-17-family miRNAs in driving CTB differentiation via promoting the extravillous and inhibiting the villous pathways into EVTs and STBs, respectively [17, 18] .
A few studies have also used PHT cells to characterize the biological function of the PE-associated DE miRNAs. Hypoxia induces the expression of many miRNAs, including miR-210 and miR-205, in cultured primary trophoblast cells [87, 99, 100] . Gain and loss of function studies by transfection of miR-210 precursors or antagomirs into primary trophoblast cells have shown that miR-210 inhibits trophoblast oxygen consumption, which might be responsible for placental mitochondria dysfunction in PE [100] . Forced miR-205 expression inhibits the expression of mediator 1 (MED1) that is known to regulate placental development [101] . In vitro, siRNAsilencing MED1 in primary CTBs perturbs the expression of several markers of trophoblast differentiation, implicating a role of miR-205 in placental adaptation to hypoxia [101] . Overexpression of PE-upregulated miR-155 [84, 102] inhibits proliferation and migration [103] , but increases syncytialization of the human first-trimester EVT-derived HTR-8/SV-neo cells [104] . Overexpression of PE-downregulated miR-195 in HTR-8/SV-neo cells promotes cell invasion via targeting Acvr2a (ActRIIA), the type II receptor for activinA and Nodal [105] . Interestingly, stable overexpression of miR-378a-5p in HTR-8/ SVneo cells enhances cell survival, migration, and invasion through downregulation of Nodal, a member of the transforming growth factor b (TGFb) superfamily [106] . In addition, miR-376c indirectly regulates Nodal-TGFb signaling. Overexpression of PE-downregulated miR-376c induces HTR-8/ SVneo cell proliferation, migration, and invasion and promotes placental explant outgrowth via targeting activin receptor-like kinase 5, a type I receptor for TGFb, and ALK7, a type I receptor for Nodal [107, 108] . The miR-378a-5p/Nodal-TGFb pathway seems to be important for placental development because knockout of Nodal in the mouse uterus results in aberrant placental development and reduced proliferation combined with increased apoptosis in the decidual basalis at the maternal-fetal interface, leading to preterm birth [109] .
The most common placental PE-associated DE miRNA, miR-210, has been demonstrated as one of the hypoxamirs, which are upregulated by hypoxia [88, [110] [111] [112] . This miRNA is evolutionarily conserved and ubiquitously expressed in different cell types and is specially induced by hypoxiainducible factor-1 alpha (HIF1A) [88, 89] via directly binding to a hypoxia-responsive element on the promoter of miR-210 [113] . Hypoxia-driven miR-210 expression promotes angiogenesis by downregulating ephrin-A3, repressing vascular endothelial growth factor (VEGFA)-dependent endothelial cell migration and tubulogenesis [88] . In addition, miR-210 can target protein-tyrosine phosphatase 1B, inhibiting VEGFA PLACENTAL microRNAs AND PREECLAMPSIA signaling in endothelial cells [114, 115] . A recent study using both rat ischemic brain cortexes and hypoxic models of human umbilical vein endothelial cells demonstrated that miR-210 activates Notch signaling and induces endothelial cell migration and tube formation [116] . Because Notch signaling plays a critical role in trophoblast endovascular invasion during placental development [117] , these data indicate an important role of miR-210 in placentation.
There are numerous studies that have shown a key role of miRNAs in angiogenesis [118, 119] . The first evidence came from a study of mouse embryos with homozygous deletion of exon 1 and 2 of Dicer gene resulting in embryo death between Days 12.5 and 14.5 of gestation with severely compromised blood vessel formation, which indicates an essential role of Dicer in mouse embryonic angiogenesis [120] . In vitro studies with cultured endothelial cells provide more evidence on the roles of Dicer in endothelial cell biology and angiogenesis processes, including proliferation, migration, capillary sprouting, and tube formation [121] [122] [123] [124] . All of these important cellular processes are required during placenta development. Recently, it has been shown that miR-155 may be important for placental angiogenesis because it targets the PE-downregulated angiogenic factor cysteine-rich angiogenic inducer 61 [102, 125, 126] that promotes cell proliferation, differentiation, and adhesion [127] . Although how miRNA regulates placental angiogenesis is unknown, this is an important area that warrants further investigation because angiogenesis is critical for the formation and expansion of the maternal, fetal, and placental interface vascular network that carries out bidirectional maternal-fetal exchanges [1, 128, 129] .
miR-17-FAMILY miRNAs (miR-17, miR-20a, AND miR20b) AND ephrinB2/Eph RECEPTOR B4 IN THE PLACENTA
By using microarray and real-time quantitative PCR analysis, we have identified significantly greater levels of miR-17, miR-20a, and miR-20b in PE versus normotensive term human placentas (n ¼ 10/group) [71] . They comprise the miR-17 family that belongs to the miR-17-92 cluster important for angiogenesis [118, 119] . The cluster contains six miRNAs, including miR-17, miR-18, miR-19a, miR-19b-1, miR-20a, and miR-92a-1, that are processed from a common precursor transcript. Based on their seed sequences, they are grouped into four families: the miR-17 family (miR-17 and miR-20a), the miR-18 family, the miR-19 family, and the miR-92 family. The cluster has two paralogs in mammals, miR-106a-363 and miR106b-25, that are derived from ancient gene duplications. They contain homologous miRNAs to those encoded by miR-17-92 [130] . The miRNA miR-20b is located in the miR-106a-363 cluster and belongs to the miR-17 family. Sequence analysis revealed that miR-17, miR-20a, and miR-20b share identical seed sequence [71] , leading to an assumption that they possibly possess overlapping functions by targeting similar sets of genes. Bioinformatics analysis using target prediction databases suggests many putative target genes of miR-17, miR-20a, and miR-20b, including HIF1A, interleukin 8, tissue inhibitor of metalloproteinase 2, matrix metallopeptidase 2, VEGFA, ephrin-B2 (EFNB2) and Eph receptor B4 (EPHB4).
Among the potential targets of miR-17-family miRNAs, EFNB2 and EPHB4 are of importance because they have been shown to play a critical role in directing CTB invasion toward the EFNB2-expressing uterine spiral arterioles, but not the EPHB4-expressing uterine veins at the maternal-fetal interface during early human placentation [131] . EPHB4 and EFNB2 are the molecular markers of veins and arterials [132] , respectively; they belong to the large family of Eph receptor tyrosine kinases and their ephrin ligands, respectively. EFNB2 is a membranebound molecule that acts via close cell contact (up to 20 nm) to control not only arterial endothelial cell growth but also the motility and adhesion of vascular smooth muscle cells and pericytes for growing arterial endothelial cell tubes [133] . EFNB2 binds its receptor EPHB4 specifically with very high affinity. EPHB4 expression occurs in veins of all diameters [134] ; it has been implicated in tumor angiogenesis and is considered a target for antiangiogenic tumor therapy [135] . Because both EFNs and EPHs are receptor tyrosine kinases, ligation induces bidirectional signaling that is essential and specific for delineating arterial-venous boundaries [136] . EFNB2 forward signaling through EPHB4 receptor inhibits cell adhesion, whereas EPHB4 reverse signaling to EFNB2 induces cell attachment [137, 138] and differentiation [139] . Interaction of Eph receptors and cell surface-bound ephrin ligands induces signal transduction into both receptor-and ligand-expressing cells, mediating various cellular responses such as cell adhesion, repulsion, and migration [140, 141] . It is also possible that they possess a role in angiogenesis because of a proangiogenic function of EFNB2 in regulating the internalization and signaling activities of VEGFA receptor VEGFR2 and VEGFR3 in endothelial cells [142, 143] .
During human pregnancy, the trophoblast expressions of both EFNB2 and EPHB4 are significantly decreased with gestation stage and are involved in building the functional placental structures [144, 145] [117, 131, 146] . During mouse pregnancy, trophoblasts express high levels of EFNB2 and EPHB4 at early Gestational Day 6.5 (gd6.5) and both decrease continuously during the course of gestation, implicating their critical roles in placental development. Meanwhile, the phenotype of spiral arteries switches from EFNB2 þ /EPHB4 À at gd6.5 to EFNB2 þ / EPHB4 þ at gd10.5 and onwards [147] , possibly because of increased blood flow, because shear has been found to increase arterial EPHB4 expression in tumors [148] . This switch may reduce trophoblast-mediated spiral artery remodeling by repulsing trophoblast cells to signal the completion of placentation.
It is noteworthy that until we have verified both EFNB2 and EPHB4 as the direct targets of miR-17-family miRNAs by luciferase reporter gene expression assays and gain and loss of function studies [71] , how placental EFNB2/EPHB4 expression is regulated has never been reported. In addition, we have also observed significantly lower EFNB2 mRNA expression in severe PE versus normotensive term placentas [71] . In keeping with the inverse relationship between placental expressions of miR-17-family miRNAs and EFNB2/EPHB4 in severe PE versus normotensive term placentas and the known functions of EFNB2/EPHB4 in mouse and human placentation, it is highly suspicious that miR-17-family miRNAs play key roles in trophoblast differentiation, invasion, endovascular transformation, and spiral artery remodeling during placental development via regulating EFNB2 and EPHB4 expression.
CHEN AND WANG

PERSPECTIVES: A miR-17/EFNB2-EPHB4 PATHWAY FOR THE PATHOGENESIS OF PE
We have recently shown that miR-17-family miRNAs negatively regulate EFNB2-EPHB4 expression in human placentas because of the following observations [71] . First, by using microarray and real-time RT-PCR we have found that miRNA-17-family miRNAs are upregulated in human placentas complicated by PE compared with normotensive pregnancies, which is inversely correlated to EFNB2 expression in placenta. Second, bioinformatics analysis predicts the direct binding of miR-17-family miRNAs to the 3 0 UTR of EFNB2 and EPHB4, which is confirmed by luciferase reporter assays. Third, overexpression of miR-17-family miRNAs downregulates EFNB2 whereas transfection of miR-17 antagomirs upregulates EPHB4 expression in BeWo cells [71] . On the other hand, work from Fisher's group has elegantly shown that EPHB4 and EFNB2 play a critical role in regulating trophoblast differentiation and migration during early human placental development because of the following findings. EPHB4 and EFNB2 are DE in different populations of trophoblasts. CTB progenitors and STB in placenta express high levels of EPHB4. When CTB progenitors differentiate into invasive CTBs, EPHB4 expression is downregulated, with a concomitant upregulation of EFNB2 and other members of the EFN/EPH family such as EFNB1 and EPHB2. The invasive CTBs that line maternal spiral arteries, i.e., the endovascular subpopulation of CTBs, also express high levels of EFNB2, B1, and EPHB2. When CTB progenitors are cultured on laminin substrates that are spotted with either recombinant EFNB2 or EPHB4 proteins, they specially avoid substrates containing EPHB4, but not EFNB2. CTBs rapidly migrate to the EFNB2-expressing NIH 3T3 cells to form aggregates when cocultured, whereas CTB migration is largely inhibited by coculture with EPHB4-expressing NIH 3T3 cells [131] . Moreover, endometrial EFNB2/EPHB4 expression changes during mouse pregnancy. The spiral arteries transit from an EFNB2 þ -high state to an EFNB2 þ -low state accompanied by a strong gain of EPHB4 expression between gd10.5 and 12.5. The gain of EPHB4 expression by midgestation spiral arteries may serve as a repulsion signal for completion of spiral artery remodeling [147] .
The aforementioned findings lead us to propose a novel miR-17/EFNB2-EPHB4 pathway for regulating early placental development, which may contribute to the pathogenesis of PE as follows. During normal placentation, low levels of miR-17-family miRNAs allow higher expression of EPHB4 and EFNB2 in the placenta. This facilitates the differentiation of CTB progenitors into EVTs for invading the maternal decidua and for remodeling the uterine spiral arteries. Therefore, the   FIG. 2 . A putative miRNA pathway for placental development and the pathogenesis of PE. During normal placentation, low levels of miR-17-family miRNAs (mir-17, miR-20a, and miR-20b) allow higher expression of EPHB4 and EFNB2 in the placenta. This facilitates the differentiation of CTB progenitors into invasive EVTs for invading the maternal decidua and for remodeling the uterine spiral arteries. The spiral arteries are transformed into lowresistance vessels with a much-reduced pressure, thereby causing blood flow to rise for facilitating the bidirectional mother-fetus exchanges of nutrients and respiratory gases (oxygen and carbon dioxide) and exclusion of fetal metabolic wastes. However, during abnormal placentation in PE, increased miR-17-family miRNAs suppress EFNB2/EPHB4 expression, further inhibiting endovascular transformation of CTBs and invasion of EVTs for spiral artery remodeling. Failed spiral artery remodeling constrains maternal-fetal interface blood flow, which contributes to the pathogenesis of PE.
PLACENTAL microRNAs AND PREECLAMPSIA uterine arteries can be transformed into low-resistance vessels to facilitate increased blood flow with a much-reduced pressure, thereby facilitating the bidirectional mother-fetus exchanges of nutrients and respiratory gases (oxygen and carbon dioxide) and exclusion of fetal metabolic wastes. However, during abnormal placentation in PE, increased miR-17-family miRNAs suppress the expression of EFNB2 and EPHB4; deregulated EFNB2/EPHB4 expression further inhibits endovascular transformation of CTBs and invasion of EVTs for spiral artery remodeling. Failed remodeling of spiral artery will constrain maternal-fetal interface blood flow, which contributes to the pathogenesis of PE (Fig. 2) .
